Skip to main content
Belgian Biosafety Server
Search form
Search
EN
FR
NL
Toggle navigation
Home
Notification procedures
Contained use GMOs/pathogens
Brussels-Capital
Flanders
Wallonia
Supporting tools
Emergency plans GMMs
Some figures
Clinical Trials GMOs
Supporting tools
Database
Some figures
Environmental release GMOs for R&D
Supporting tools
Database
Some figures
Commercialisation medicinal GMOs
Supporting tools
Some figures
Authorisations GMO-human
Authorisations GMO-veterinary
Commercialisation GMOs environment or food/feed
Supporting tools
Some figures
Dossier C/BE/96/01
Regulatory framework
EU framework
Contained use GMMs
Deliberate release GMOs
Decisions releases GMOs
GM Food/Feed
Medicinal GMOs
Worker's protection
Other regulations
Belgian framework
Cooperation agreement
Historical steps
Biosafety Council
SBB
Contained use GMOs/pathogens
Certification and exemptions
Historical perspective
Deliberate release GMOs
Historical background
Scientific assessment
NRL-GMO
Worker's protection
Thematic Areas
Assessment bio-risks
Biosecurity
LAI
Genome editing
Polio eradication
Synthetic biology
Transport
Historical Background
Biological risk classification
Recombinant DNA
GMO - From lab to field
OECD activities
EU GMO Directives
EU GMO definition
FAQ
Events
Upcoming Events
Past Events
Our events
MEACB 2017
Biosafety training (HE2B)
About the SBB
Tasks and activities
Risk assessment
Scientific support
International
Networking activities of the SBB
Research
Communication
Publications
Contact Us
* NEW (25-06-2025) *
schering n.v./s.a.
themis bioscience gmbh
Search the database for deliberate release of GM medicinal products
Search the database for deliberate release of GM medicinal products
Displaying 1 - 6 of 6
Fulltext search
Search
Reset
EU record number
Title
Company / Sponsor
Treated organism
Genetic modification
Only notified under the "contained use" procedure. Dossier submitted on
18/02/2020
.
A phase III, randomized observer blinded, placebo-controlled, multi-center study, to evaluate safety and immunogenicity of the Chikungunya vaccine MV-CHIK in healthy adults
Themis Bioscience GmbH
Humans
Recombinant measles virus vaccine strain (Schwarz strain) expressing env (E1, E2, E3), capsid C en structural protein 6K from CHIKV
Only notified under the "contained use" procedure. Dossier submitted on
23/07/2019
.
A phase 1, randomized, placebo-controlled trial, to evaluate the optimal dose of MV-LASV, a new vaccine against LASSA virus infection, regarding safety, tolerability and immunogenicity in healthy volunteers, consisting of an unblinded dose escalation and
Themis Bioscience GmbH
Humans
Recombinant measles virus vaccine strain (Schwarz strain) expressing the envelop glycoprotein GPC and the nucleoprotein NP with a mutated exonuclease domein (GCP-rNP) from Lassavirus
B/BE/03/B3
Phase I multicentre study of TG1024 (Adenovirus interleukin 2) in patients with metastatic melanoma or other advanced solid tumor cancers
Transgene S.A.
Humans
gene coding for human interleukin 2
B/BE/02/B7
Phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in patients with metastatic Renal Cell Carcinoma (RCC)
Transgene S.A.
Humans
sequences coding for the human MUC-1 antigen and IL-2
Only notified under the "contained use" procedure. Dossier submitted on
11/07/2002
.
A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina
Schering N.V./S.A.
Humans
human FGF-4
B/BE/01/B7
Specific immunotherapy against MUC-1 antigen - Study TG4010.04 : "Phase II study with TG4010(MVA-MUC-1-IL-2) in patients with metastatic breast cancer", Study TG4010.05 : "Phase II study with TG 4010 in patients with non small cell lung cancer"
Transgene S.A.
Humans
sequences coding for the human MUC-1 antigen and IL-2
Showing 1 to 6 of 6 entries
